Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 128

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 128
---
uable upon the exercise of pre-funded warrants issued in the private placement at an exercise price of $0.80 per warrant, for aggregate gross proceeds of approximately $6.0 million. We also issued unregistered placement agent warrants to purchase a total of 536,800 Ordinary Shares represented by 52 Depositary Shares toLadenburg Thalman & Co. Inc. at an exercise price of $10,000.00 per warrant for one warrants and an exercise price of $5,800.00 per warrant for 51 warrants, and Series A Warrants to purchase 625,000 Ordinary Shares represented by 62 Depositary Shares at an exercise price of $5,360.00 per warrant to an investor pursuant to a waiver.

On
May 26, 2023, we completed the closing of the May 2023 Registered Direct Offering, with institutional investors of (1) 166,017,700 Ordinary
Shares represented by 16,601 Depositary Shares, issuable upon the exercise of the Series C Warrants at an exercise price of $400.00 per
warrant, (2) 110,675,600 Ordinary Shares represented 11,059 Depositary Shares issuable upon the exercise of the Series D Warrants at an
exercise price of $400.00 per warrant and, (3) 4,426,800 Ordinary Shares represented by 442 Depositary Shares issuable upon the exercise
of the May 2023 Placement Agent Warrants at an exercise price of $375.00 per warrant.

On
June 20, 2023 we issued the Series C warrants, Series D warrants and placement agent warrants to the investors and the placement agent
after receiving required shareholder approval of the allotment of, and disapplication of pre-emption rights with respect to the Ordinary
Shares to be issued under the Series C warrants, Series D warrants and placement agent warrants at our general meeting held on June 14,
2023.

| II-1 |

On December 21, 2023, in two
private placement transactions, we issued (i) an aggregate of 8,997 Depositary Shares to certain secured noteholders in satisfaction of
the Adhera Therapeutics, Inc., and (y) an aggregate of 90,999 pre-funded warrants to purchase Depositary Shares to certain of the secured
noteholders, and (ii) issued to Melior Pharmaceuticals I, Inc. 14,177 of our Depositary Shares.

On February 26,